Cornelius J R, Salloum I M, Haskett R F, Ehler J G, Jarrett P J, Thase M E, Perel J M
Department of Psychiatry, University of Pittsburgh School of Medicine, PA 15213, USA.
Addict Behav. 1999 Jan-Feb;24(1):111-4. doi: 10.1016/s0306-4603(98)00050-1.
The aim of this analysis was to evaluate the efficacy of the SSRI antidepressant fluoxetine versus placebo for the marijuana use of depressed alcoholics. There are no previous reports involving and SSRI antidepressant for marijuana abuse. This analysis involved a subsample of 22 depressed alcoholic marijuana users out of a total of 51 depressed alcoholics. The entire sample was involved in a 12-week double-blind, placebo-controlled study evaluating the efficacy of fluoxetine versus placebo in depressed alcoholics. During the course of the trial, the cumulative number of marijuana cigarettes used was almost 20 times as high in the placebo group as in the fluoxetine group. Also, the number of days of marijuana use during the study was five times higher in the placebo group than in the fluoxetine group. These data suggest efficacy for fluoxetine in decreasing marijuana use of depressed alcoholics.
该分析的目的是评估选择性5-羟色胺再摄取抑制剂（SSRI）类抗抑郁药氟西汀与安慰剂相比，对抑郁型酗酒者吸食大麻情况的疗效。此前尚无关于使用SSRI类抗抑郁药治疗大麻滥用的报道。该分析涉及51名抑郁型酗酒者中的22名抑郁型酗酒大麻使用者的子样本。整个样本参与了一项为期12周的双盲、安慰剂对照研究，评估氟西汀与安慰剂对抑郁型酗酒者的疗效。在试验过程中，安慰剂组吸食大麻香烟的累积数量几乎是氟西汀组的20倍。此外，研究期间安慰剂组吸食大麻的天数比氟西汀组高5倍。这些数据表明氟西汀在减少抑郁型酗酒者吸食大麻方面具有疗效。
